According to the research report, the global cancer monoclonal antibodies market size is expected to touch USD 410.95 Billion by 2032, from USD 75.14 Billion in 2022, growing with a significant CAGR of 18.52% from 2023 to 2032.
The cancer monoclonal antibodies report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global cancer monoclonal antibodies in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global cancer monoclonal antibodies market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global cancer monoclonal antibodies during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/2981
This study covers a detailed segmentation of the global cancer monoclonal antibodies market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global cancer monoclonal antibodies market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- Amgen Inc
- Eli Lilly and Company
- Merck & Co., Inc
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Bristol Myers Squibb Co.
- GlaxoSmithKline plc
- Johnson & Johnson
- AstraZeneca plc
- AbbVie
Market Segmentation
By Type
- Humanized
- Human
- Chimeric
- Murine
By Application
- Blood Cancer
- Breast Cancer
- Lung Cancer
- Melanoma
- Colorectal Cancer
- Liver Cancer
- Others
By Monoclonal Antibody Therapies
- Bevacizumab (Avastin)
- Rituximab (Rituxan)
- Trastuzumab (Herceptin)
- Cetuximab (Erbitux)
- Panitumumab (Vectibix)
- Other Monoclonal Antibody Therapies
By End-User
- Hospitals
- Research Institutes
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global cancer monoclonal antibodies report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global cancer monoclonal antibodies market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Monoclonal Antibodies Market
5.1. COVID-19 Landscape: Cancer Monoclonal Antibodies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Monoclonal Antibodies Market, By Type
8.1. Cancer Monoclonal Antibodies Market, by Type, 2023-2032
8.1.1. Humanized
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Human
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Chimeric
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Murine
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Cancer Monoclonal Antibodies Market, By Application
9.1. Cancer Monoclonal Antibodies Market, by Application, 2023-2032
9.1.1. Blood Cancer
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Breast Cancer
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Lung Cancer
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Melanoma
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Colorectal Cancer
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Liver Cancer
9.1.6.1. Market Revenue and Forecast (2020-2032)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Cancer Monoclonal Antibodies Market, By Monoclonal Antibody Therapies
10.1. Cancer Monoclonal Antibodies Market, by Monoclonal Antibody Therapies, 2023-2032
10.1.1. Bevacizumab (Avastin)
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Rituximab (Rituxan)
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Trastuzumab (Herceptin)
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Cetuximab (Erbitux)
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Panitumumab (Vectibix)
10.1.5.1. Market Revenue and Forecast (2020-2032)
10.1.6. Other Monoclonal Antibody Therapies
10.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Cancer Monoclonal Antibodies Market, By End-User
11.1. Cancer Monoclonal Antibodies Market, by End-User, 2023-2032
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Research Institutes
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Cancer Monoclonal Antibodies Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Type (2020-2032)
12.1.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.1.4. Market Revenue and Forecast, by End-User (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.2.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.3.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.4.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Monoclonal Antibody Therapies (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End-User (2020-2032)
Chapter 13. Company Profiles
13.1. Amgen Inc
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eli Lilly and Company
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck & Co., Inc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Novartis AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. F. Hoffmann-La Roche Ltd.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Bristol Myers Squibb Co.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. GlaxoSmithKline plc
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Johnson & Johnson
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. AstraZeneca plc
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. AbbVie
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments